<DOC>
	<DOCNO>NCT02921971</DOCNO>
	<brief_summary>Primary Objective : To evaluate , comparison placebo , efficacy SAR156597 administer subcutaneously 24 week skin fibrosis patient dcSSc . Secondary Objectives : - To evaluate efficacy SAR156597 compare placebo physical/functional disability patient dcSSc . - To evaluate efficacy SAR156597 compare placebo respiratory function patient dcSSc . - To evaluate safety profile SAR156597 compare placebo patient dcSSc . - To evaluate potential immunogenicity ( anti-drug antibody [ ADA ] response ) SAR156597 patient dcSSc . - To evaluate pharmacokinetics ( PK ) ( trough plasma concentration ) SAR156597 administer subcutaneously 24 week .</brief_summary>
	<brief_title>Effectiveness Safety SAR156597 Treating Diffuse Systemic Sclerosis</brief_title>
	<detailed_description>The total study duration per patient 39 week ; consist 4-week screening , 24-week study treatment period , 11-week follow-up study drug treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Inclusion criterion : Systemic Sclerosis accord American College Rheumatology/The European League Rheumatism ( ACR/EULAR ) 2013 criterion . Diffuse cutaneous form SSc accord Leroy 's criterion . Able willing sign write informed consent form comprehension content comply requirement study protocol . Exclusion criterion : Aged &lt; 18 year . Disease duration &gt; 36 month time first nonRaynaud 's phenomenon manifestation . Modified Rodnan Skin Score ( mRSS ) &lt; 10 &gt; 35 screen baseline visit . History vasculitis , active remission . Diagnosis connective tissue disease ( SSc ) overlap syndrome ( eg , polymyositis/scleroderma ) . Positive Human Immunodeficiency Virus ( HIV ) serology know history HIV infection , active remission . Abnormal hepatitis B and/or hepatitis C test indicative active chronic infection : Abnormal Hepatitis B test : Positive hepatitis B surface antigen ( HBsAg ) OR positive total hepatitis B core antibody ( HBcAb ) negative hepatitis B surface antibody ( HBsAb ) OR positive total hepatitis B core antibody positive HBsAb presence hepatitis B DNA ( HBV DNA ) . Abnormal Hepatitis C test : Positive antiHCV Ab positive HCV RNA . Positive 2 confirmed indeterminate QuantiferonTB Gold test screen ( regardless prior treatment status ) . Serious infection ( eg , pneumonia , pyelonephritis ) within 4 week screen , infection require hospitalization intravenous antibiotic within 4 week screen chronic bacterial infection ( eg , osteomyelitis ) . History anaphylaxis biologic therapy . Evidence clinically significant , severe unstable , acute chronically progressive , uncontrolled infection medical condition ( eg , cerebral , cardiac , pulmonary , renal , hepatic , gastrointestinal neurologic SSc SScILD ) previous , active pending surgical disorder , condition may affect patient safety judgment Investigator . Any prior history malignancy active malignancy , include lymphoproliferative disease ( except successfullytreated carcinoma insitu cervix , nonmetastatic squamous cell basal cell carcinoma skin ) within 5 year prior baseline . Clinically significant abnormal electrocardiogram ( ECG ) screening may affect conduct study judgment Investigator . High dose steroid ( &gt; 10 mg/day prednisolone equivalent ) ; change steroid dose within 4 week prior screen screen period ; expect change course study . Previous treatment rituximab within 12 month prior screen . Previous treatment bone marrow transplantation , total lymphoid irradiation ablative ultrahigh dose cyclophosphamide . Treatment high dose immunosuppressive drug ( eg , cyclophosphamide &gt; 1 mg/kg oral/day &gt; 750 mg IV/month ; azathioprine &gt; 100 mg/day ; methotrexate &gt; 15 mg/week ; mycophenolate mofetil &gt; 2 g/day ) within 3 month screen change dose within 4 week prior randomization ( baseline visit ) ; expect change course study . Treatment etanercept , cyclosporine A , intravenous immunoglobulin ( IVIG ) , rapamycin , Dpenicillamine , tyrosine kinase inhibitor within 4 week screen antithymocyte globulin within 6 month screen . Treatment infliximab , certolizumab , golimumab , abatacept , adalimumab , tocilizumab within 8 week screen anakinra within 1 week screening . Treatment investigational drug within 1 month screening , 5 halflives , know ( whichever longer ) . Abnormal laboratory test screen : Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2 time upper limit normal range ( ULN ) ; Hemoglobin &lt; 11 g/100 mL male &lt; 10 g/100 mL female ; Neutrophils &lt; 1500/mm^3 ( except &lt; 1000/mm3 African descent ) ; Platelets &lt; 100 000/mm^3 ; Creatinine ≥150 µmol/L . Note : Laboratory parameter may repeat screen period felt spurious due technical error order determine eligibility . Current history substance and/or alcohol abuse Current employee Sanofi immediate family member ( eg , spouse , parent , child sibling ) current employee Sanofi . Currently incarcerate anticipated/scheduled incarcerated course study . Any condition circumstance preclude patient follow complete protocol requirement , opinion Investigator . Pregnant breastfeed woman Women childbearing potential protect highlyeffective contraceptive method ( ) birth control ( define inform consent form and/or Appendix G United Kingdom ) , and/or unwilling unable test pregnancy . Note : Women childbearing potential must confirm negative pregnancy test screen randomization visit . They must use effective contraceptive method throughout entire duration study treatment , least 12 week last administration IMP . Postmenopausal woman must amenorrheic least 12 month . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>